praluent
Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk
March 18, 2019Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent
Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …
Positive CHMP recommendation for Sanofi’s atherosclerotic CVD drug Praluent
February 4, 2019Sales and Marketing Europe, atherosclerotic cardiovascular disease, cvd, pharma, praluent
It has been announced that Sanofi’s Praluent (alirocumab) has been awarded a positive recommendation from the European Medicines Agency’s Committee …
Sanofi/Regeneron forced to slash price in wake of slow sales
May 1, 2018Research and Development, Sales and Marketing Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical, praluent
Sanofi and Regeneron were touted as having a sure-fire blockbuster on their hands when they first brought Praluent to market …
Sanofi and Regeneron reveal strong data and a price drop for Praluent
March 12, 2018Research and Development, Sales and Marketing Regeneron, Sanofi, pharma, praluent
Sanofi and Regeneron have revealed strong new data for its PCSK9 inhibitor Praluent showing the first-ever reduction in deaths within …
Sanofi and Regeneron posts positive Praluent cholesterol data
June 12, 2017Research and Development, Sales and Marketing Regeneron, Sanofi, praluent
Sanofi and Regeneron were able to update its PCSK9 therapy Praluent with the positive data showing it could reduce levels …
Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent
February 9, 2017Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent
Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …
Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
August 17, 2016Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent
A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
Amgen wins high-profile cholesterol drug patent case v Sanofi
March 17, 2016Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent
A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …
Sanofi and Regeneron heart drug Praluent available in UK
October 19, 2015Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent
Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …
Sanofi and Regeneron given European nod for Praluent
September 28, 2015Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent
The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent. The heart drug is …
NHS looks to ESC for next-gen heart drug data
August 28, 2015Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent
New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …
FDA and EMA approve heart drug Praluent
July 27, 2015Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent
The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …
Praluent scores positive trial results in Japan
July 9, 2015Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent
Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …
Sanofi and Amgen cholesterol drugs shine
March 16, 2015Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent
Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
